In-Depth Immunological Typization of Children with Sickle Cell Disease: A Preliminary Insight into Its Plausible Correlation with Clinical Course and Hydroxyurea Therapy.
Giulia GiuliettiDaniele ZamaFrancesca ContiMattia MorattiMaria Teresa PresuttiTamara BelottiMaria Elena CantariniElena FacchiniMirna BassiPaola SelvaElisabetta MagriniMarcello LanariAndrea PessionPublished in: Journal of clinical medicine (2022)
Sickle cell disease (SCD) is a condition of functional hypo-/a-splenism in which predisposition to bacterial infections is only a facet of a wide spectrum of immune-dysregulation disorders forming the clinical expression of a peculiar immunophenotype. The objective of this study was to perform an in-depth immunophenotypical characterization of SCD pediatric patients, looking for plausible correlations between immunological biomarkers, the impact of hydroxyurea (HU) treatment and clinical course. This was an observational case-control study including 43 patients. The cohort was divided into two main groups, SCD subjects (19/43) and controls (24/43), differing in the presence/absence of an SCD diagnosis. The SCD group was split up into HU+ (12/19) and HU- (7/19) subgroups, respectively receiving or not a concomitant HU treatment. The principal outcomes measured were differences in the immunophenotyping between SCD patients and controls through chi-squared tests, t-tests, and Pearson's correlation analysis between clinical and immunological parameters. Leukocyte and neutrophil increase, T-cell depletion with prevalence of memory T-cell compartment, NK and B-naïve subset elevation with memory and CD21low B subset reduction, and IgG expansion, significantly distinguished the SCD HU- subgroup from controls, with naïve T cells, switched-memory B cells and IgG maintaining differences between the SCD HU+ group and controls ( p -value of <0.05). The mean CD4+ central-memory T-cell% count was the single independent variable showing a positive correlation with vaso-occlusive crisis score in the SCD group (Pearson's R = 0.039). We report preliminary data assessing plausible clinical implications of baseline and HU-related SCD immunophenotypical alterations, which need to be validated in larger samples, but potentially affecting hypo-/a-splenism immuno-chemoprophylactic recommendations.
Keyphrases
- sickle cell disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- working memory
- chronic kidney disease
- prognostic factors
- poor prognosis
- public health
- peritoneal dialysis
- randomized controlled trial
- young adults
- stem cells
- skeletal muscle
- metabolic syndrome
- risk factors
- insulin resistance
- machine learning
- mesenchymal stem cells
- electronic health record
- long non coding rna
- peripheral blood
- bone marrow
- artificial intelligence
- combination therapy
- big data
- cross sectional
- replacement therapy
- glycemic control
- cell therapy
- flow cytometry